The big news this week—and, for that matter, this year—is Roche’s offer to buy the 44 percent of Genentech that it doesn’t already own. The blogosphere is burning with all the predictable predictions, dire and otherwise, attendant on a big pharma takeover of a biotech. The phrase “killing the goose that’s been laying the golden [...]

[Read more →]

An estimated one thousand clinical trials have been conducted for gene therapies in the past 20 years, but to date, not a single drug has made it to FDA approval. However, we may be a step closer as Introgen today announced that it has filed applications with FDA and EMEA for marketing approval of Advexin, [...]

[Read more →]